Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01888978 · ClinicalTrials.gov registry record · Phase 2
Molecularly Tailored Therapy for Pancreas Cancer
A Phase 2 study of Pancreatic Cancer, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT01888978 is a Phase 2 study of Pancreatic Cancer that has completed, run by Georgetown University. The registered enrollment target is 19 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT01888978, a Phase 2 study of Pancreatic Cancer, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
Patient therapy is tailored according to the molecular profile of the patient's tumor.
Conditions Studied
Interventions
- DRUG Gem-OX
- DRUG Gem-5FU
- DRUG Gem-Tax
- DRUG Modified FOLFOX-6
- DRUG Ox-Tax
Study Locations (2)
District of Columbia
- Georgetown University- Lombardi Comprehensive Cancer Center - Washington D.C.
Maryland
- MedStar Montgomery Medical Center - Olney
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-12 |
| Est. Completion | 2018-01-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01888978
The ClinicalTrials.gov registry entry for NCT01888978 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Gem-OX is the first listed.
NCT01888978 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT01888978 about?
NCT01888978 is a clinical study titled "Molecularly Tailored Therapy for Pancreas Cancer". Patient therapy is tailored according to the molecular profile of the patient's tumor.
What is the current status of trial NCT01888978?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2012-12. Estimated completion is 2018-01-24.
What conditions does trial NCT01888978 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT01888978?
The interventions under investigation include: Gem-OX (DRUG), Gem-5FU (DRUG), Gem-Tax (DRUG), Modified FOLFOX-6 (DRUG), Ox-Tax (DRUG).
Who is sponsoring clinical trial NCT01888978?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01888978 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.